GlassScriptPhysician profile
Scott M Warden
NPI 1407910748
$1,519.07
in general payments reported to CMS, 2019-2025
12 companies · $331 in 2025
The $331 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $21.07 · 2021: $125 · 2022: $219 · 2023: $267 · 2024: $325 · 2025: $331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $923.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $922.76 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $556.50 | 2021-2025 | Vabysmo, Lucentis, Susvimo |
| Regeneron Healthcare Solutions, INC. | $373.70 | 2021-2025 | Eylea Hd, Eylea |
| Dutch Ophthalmic, USA | $158.90 | 2019 | |
| Alimera Sciences, INC. | $131.95 | 2022-2024 | Iluvien, Yutiq |
| Allergan, INC. | $108.60 | 2019-2021 | |
| Astellas Pharma US INC | $39.38 | 2024 | Izervay |
| Abbvie INC. | $38.52 | 2025 | |
| Ani Pharmaceuticals, INC. | $31.72 | 2025 | Purified Cortrophin Gel |
| Apellis Pharmaceuticals, INC. | $23.95 | 2023 | Syfovre |
| Eyepoint US, INC. | $21.79 | 2021 | |
| Coherus Oncology, INC. | $19.71 | 2023 | |
| Abiomed | $14.35 | 2024 | Impella |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Warden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.